Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Muta-MedSci.cn

Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Muta

Wang, AL; Li, XX; Chen, C; Wu, H; Qi, ZP; Hu, C; Yu, KL; Wu, JX; Liu, J; Liu, XC; Hu, ZQ; Wang, W; Wang, WL; Wang, WC; Wang, L; Wang, BL; Liu, QW; Li, LL; Ge, J; Ren, T; Zhang, SC; Xia, RX; Liu, J; Liu, QS

Liu, J; Liu, QS (reprint author), Chinese Acad Sci, High Magnet Field Lab, Mailbox 1110,350 Shushanhu Rd, Hefei 230031, Anhui, Peoples R China.; Liu, J; Liu, QS (reprint author), CHMFL HCMTC Target Therapy Joint Lab, 350 Shushanhu Rd, Hefei 230031, Anhui,

Abstract

FLT3-ITD mutant has been observed in about 30% of AML patients and extensively studied as a drug discovery target. On the basis of our previous study ......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Muta

科室

工具

服务